295 related articles for article (PubMed ID: 33374627)
1. Current Understanding of Myelomatous Mesenchymal Stromal Cells Extended through Advances in Experimental Methods.
Ichii M; Hosen N
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374627
[TBL] [Abstract][Full Text] [Related]
2. The impact of the bone marrow microenvironment on multiple myeloma (Review).
Hou J; Wei R; Qian J; Wang R; Fan Z; Gu C; Yang Y
Oncol Rep; 2019 Oct; 42(4):1272-1282. PubMed ID: 31524246
[TBL] [Abstract][Full Text] [Related]
3. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
Ria R; Vacca A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
[TBL] [Abstract][Full Text] [Related]
4. Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance.
Melaccio A; Reale A; Saltarella I; Desantis V; Lamanuzzi A; Cicco S; Frassanito MA; Vacca A; Ria R
J Clin Med; 2022 Nov; 11(21):. PubMed ID: 36362718
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
6. Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
Chen T; Moscvin M; Bianchi G
Front Oncol; 2020; 10():608815. PubMed ID: 33251153
[TBL] [Abstract][Full Text] [Related]
7. The NF-κB Activating Pathways in Multiple Myeloma.
Roy P; Sarkar UA; Basak S
Biomedicines; 2018 May; 6(2):. PubMed ID: 29772694
[TBL] [Abstract][Full Text] [Related]
8. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
9. The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity.
Poltavets V; Kochetkova M; Pitson SM; Samuel MS
Front Oncol; 2018; 8():431. PubMed ID: 30356678
[TBL] [Abstract][Full Text] [Related]
10. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
[TBL] [Abstract][Full Text] [Related]
11. An Lysophosphatidic Acid Receptors 1 and 3 Axis Governs Cellular Senescence of Mesenchymal Stromal Cells and Promotes Growth and Vascularization of Multiple Myeloma.
Kanehira M; Fujiwara T; Nakajima S; Okitsu Y; Onishi Y; Fukuhara N; Ichinohasama R; Okada Y; Harigae H
Stem Cells; 2017 Mar; 35(3):739-753. PubMed ID: 27641212
[TBL] [Abstract][Full Text] [Related]
12. Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment.
Kharouf N; Flanagan TW; Hassan SY; Shalaby H; Khabaz M; Hassan SL; Megahed M; Haikel Y; Santourlidis S; Hassan M
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370757
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment and the role of mesenchymal stromal cells.
Kucerova L; Skolekova S
Neoplasma; 2013; 60(1):1-10. PubMed ID: 23067210
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
Corso A; Ferretti E; Lazzarino M
Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
Ge Y; Zhan F; Barlogie B; Epstein J; Shaughnessy J; Yaccoby S
Br J Haematol; 2006 Apr; 133(1):83-92. PubMed ID: 16512833
[TBL] [Abstract][Full Text] [Related]
16. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.
Jakubikova J; Cholujova D; Hideshima T; Gronesova P; Soltysova A; Harada T; Joo J; Kong SY; Szalat RE; Richardson PG; Munshi NC; Dorfman DM; Anderson KC
Oncotarget; 2016 Nov; 7(47):77326-77341. PubMed ID: 27764795
[TBL] [Abstract][Full Text] [Related]
17. Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications.
Chen M; Jiang J; Hou J
Biomark Res; 2023 May; 11(1):55. PubMed ID: 37259170
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stroma: Role in osteosarcoma progression.
Cortini M; Avnet S; Baldini N
Cancer Lett; 2017 Oct; 405():90-99. PubMed ID: 28774797
[TBL] [Abstract][Full Text] [Related]
20. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
